Mapping the Binding Interface between an HIV-1 Inhibiting Intrabody and the Viral Protein Rev

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Vercruysse, Thomas ^a   Boons, Eline ^a   Venken, Tom ^b   Vanstreels, Els ^a   Voet, Arnout ^b   Steyaert, Jan ^c   De Maeyer, Marc ^b   Daelemans, Dirk ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; NB 190 ANTIBODY; REV PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; EMBRYO; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; MUTATIONAL ANALYSIS; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODY AFFINITY; CELL LINE; EPITOPE MAPPING; EPITOPES; HIV-1; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TRANSPORT; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SINGLE-DOMAIN ANTIBODIES;

HUMAN IMMUNODEFICIENCY VIRUS 1; LAMA (MAMMAL);

EID: 84875681733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060259     Document Type: Article

References (50)

1. Pollard VW, Malim MH, (1998) The HIV-1 Rev protein. Annu Rev Microbiol 52: 491-532.
2. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR, (1989) The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338: 254-257.
3. Daly TJ, Cook KS, Gray GS, Maione TE, Rusche JR, (1989) Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 342: 816-819.
4. Fornerod M, Ohno M, Yoshida M, Mattaj IW, (1997) CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051-1060.
5. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, et al. (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308-311.
6. Neville M, Stutz F, Lee L, Davis LI, Rosbash M, (1997) The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr Biol 7: 767-775.
7. Auer M, Gremlich HU, Seifert JM, Daly TJ, Parslow TG, et al. (1994) Helix-loop-helix motif in HIV-1 Rev. Biochemistry 33: 2988-2996.
8. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, et al. (1990) HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 60: 675-683.
9. Daelemans D, Costes SV, Lockett S, Pavlakis GN, (2005) Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo. Mol Cell Biol 25: 728-739.
10. Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, et al. (2004) Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J 86: 3993-4003.
11. Kalland KH, Szilvay AM, Brokstad KA, Saetrevik W, Haukenes G, (1994) The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments. Mol Cell Biol 14: 7436-7444.
12. Meyer BE, Malim MH, (1994) The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm. Genes Dev 8: 1538-1547.
13. Daelemans D, Pannecouque C, (2006) HIV-1 Rev function as target for antiretroviral drug development. Curr Opin HIV AIDS 1: 388-397.
14. Daelemans D, Costes SV, Cho EH, Erwin-Cohen RA, Lockett S, et al. (2004) In vivo HIV-1 Rev multimerization in the nucleolus and cytoplasm identified by fluorescence resonance energy transfer. J Biol Chem 279: 50167-50175.
15. Jain C, Belasco JG, (2001) Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol Cell 7: 603-614.
16. Mann DA, Mikaelian I, Zemmel RW, Green SM, Lowe AD, et al. (1994) A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 241: 193-207.
17. Daugherty MD, D'Orso I, Frankel AD, (2008) A solution to limited genomic capacity: using adaptable binding surfaces to assemble the functional HIV Rev oligomer on RNA. Mol Cell 31: 824-834.
18. Daugherty MD, Liu B, Frankel AD, (2010) Structural basis for cooperative RNA binding and export complex assembly by HIV Rev. Nat Struct Mol Biol 17: 1337-1342.
19. DiMattia MA, Watts NR, Stahl SJ, Rader C, Wingfield PT, et al. (2010) Implications of the HIV-1 Rev dimer structure at 3.2 A resolution for multimeric binding to the Rev response element. Proc Natl Acad Sci U S A 107: 5810-5814.
20. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D, (2010) An Intrabody Based on a Llama Single-domain Antibody Targeting the N-terminal {alpha}-Helical Multimerization Domain of HIV-1 Rev Prevents Viral Production. J Biol Chem 285: 21768-21780.
21. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, et al. (1993) Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
22. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S, (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414: 521-526.
23. Fisher AG, Collalti E, Ratner L, Gallo RC, Wong-Staal F, (1985) A molecular clone of HTLV-III with biological activity. Nature 316: 262-265.
24. McNally JG, (2008) Quantitative FRAP in analysis of molecular binding dynamics in vivo. Methods Cell Biol 85: 329-351.
25. Vercruysse T, Pawar S, De Borggraeve W, Pardon E, Pavlakis GN, et al. (2011) Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer. RNA Biol 8: 316-324.
26. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N, (2010) ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids. Nucleic Acids Res 38: W529-533.
27. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM, (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4: 773-783.
28. Onufriev A, Bashford D, Case DA, (2000) Modification of the generalized Born model suitable for macromolecules. Journal of Physical Chemistry B 104: 3712-3720.
29. Labute P, (2008) The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. Journal of Computational Chemistry 29: 1693-1698.
30. Wang JM, Cieplak P, Kollman PA, (2000) How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? Journal of Computational Chemistry 21: 1049-1074.
31. Venken T, Daelemans D, De Maeyer M, Voet A Computational investigation of the HIV-1 Rev multimerization using molecular dynamics simulations and binding free energy calculations. Submitted for publication.
32. Hess B, Kutzner C, van der Spoel D, Lindahl E, (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation 4: 435-447.
33. Jarvis RA, Patrick EA, (1973) Clustering Using a Similarity Measure Based on Shared near Neighbors. Ieee Transactions on Computers C-22: 1025-1034.
34. Dominguez C, Boelens R, Bonvin AMJJ, (2003) HADDOCK: A protein-protein docking approach based on biochemical or biophysical information. Journal of the American Chemical Society 125: 1731-1737.
35. Malim MH, Bohnlein S, Hauber J, Cullen BR, (1989) Functional dissection of the HIV-1 Rev trans-activator-derivation of a trans-dominant repressor of Rev function. Cell 58: 205-214.
36. Fang J, Acheampong E, Dave R, Wang F, Mukhtar M, et al. (2005) The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes. Virology 336: 299-307.
37. Yedavalli VS, Neuveut C, Chi YH, Kleiman L, Jeang KT, (2004) Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119: 381-392.
38. Fang J, Kubota S, Yang B, Zhou N, Zhang H, et al. (2004) A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev. Virology 330: 471-480.
39. Neumann M, Felber BK, Kleinschmidt A, Froese B, Erfle V, et al. (1995) Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. J Virol 69: 2159-2167.
40. Ludwig E, Silberstein FC, van Empel J, Erfle V, Neumann M, et al. (1999) Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes. J Virol 73: 8279-8289.
41. Robertson-Anderson RM, Wang J, Edgcomb SP, Carmel AB, Williamson JR, et al. (2011) Single-molecule studies reveal that DEAD box protein DDX1 promotes oligomerization of HIV-1 Rev on the Rev response element. J Mol Biol 410: 959-971.
42. Yin H, Hamilton AD, (2005) Strategies for targeting protein-protein interactions with synthetic agents. Angewandte Chemie-International Edition 44: 4130-4163.
43. Lin PF, Blair W, Wang T, Spicer T, Guo Q, et al. (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci U S A 100: 11013-11018.
44. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, et al. (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology 6: 442-448.
45. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
46. Daelemans D, Afonina E, Nilsson J, Werner G, Kjems J, et al. (2002) A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A 99: 14440-14445.
47. Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, et al. (2008) Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 16: 9487-9497.
48. Shangary S, Wang S, (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
49. Zheng CH, Zhou YJ, Zhu J, Ji HT, Chen J, et al. (2007) Construction of a three-dimensional pharmacophore for Bcl-2 inhibitors by flexible docking and the multiple copy simultaneous search method. Bioorg Med Chem 15: 6407-6417.
50. Lefranc MP, (2004) IMGT, The International ImMunoGeneTics Information System, Methods Mol Biol. 248: 27-49http://imgt.cines.fr.